Means and Methods for Determining a Clearance Normalized Amount of a Metabolite Disease Biomarker in a Sample
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to a method for determining a clearance normalized amount of a metabolite disease biomarker in a sample including the steps of (a) determining the amount of the disease biomarker in at least a first type of sample of a subject suspected to suffer from the disease, (b) determining the amount of a kidney function biomarker which correlates with the glomerular filtration rate (GFR) in the said at least first type of sample, and (c) determining a clearance normalized amount for the metabolite disease biomarker by normalizing the amount determined for the metabolite disease biomarker in step (a) to the amount of the kidney function biomarker determined in step (b). Moreover, the invention also relates to a method for diagnosing a disease in a subject suspected to suffer therefrom and to a device for determining a clearance normalized amount of a metabolite disease biomarker in a sample.
1 Citation
26 Claims
-
1-14. -14. (canceled)
-
15. A method for determining a clearance normalized amount of a metabolite disease biomarker in a sample comprising the steps of:
-
(a) determining the amount of the metabolite disease biomarker in at least a first type of sample of a subject suspected to suffer from the disease; (b) determining the amount of a kidney function biomarker which correlates with the glomerular filtration rate (GFR) in the said at least first type of sample; and (c) determining a clearance normalized amount for the metabolite disease biomarker by normalizing the amount determined for the metabolite disease biomarker in step (a) to the amount of the kidney function biomarker determined in step (b), wherein said sample is blood or a derivative thereof. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23)
-
-
24. A device for determining a clearance normalized amount of a metabolite disease biomarker in a sample comprising:
-
(a) an analyzing unit comprising a detection agent which specifically detects the amount of at least one metabolite disease biomarker and a detection agent which specifically detects the amount of a kidney function biomarker; and (b) an evaluation unit comprising a data processor having tangibly embedded a computer program code carrying out an algorithm which normalizes the amount for the metabolite disease biomarker to the amount of the kidney function biomarker. - View Dependent Claims (25, 26)
-
Specification